Latest Commercial Rollouts News

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Vitasora Health has completed the first tranche of its $11 million capital raise, positioning the company to fund growth initiatives and reach cash flow breakeven in the second half of fiscal 2026.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

Janus Electric has secured a three-year supply deal with Electrovaya to develop advanced lithium-ion battery packs, promising safer, longer-lasting, and lighter batteries for zero-emission heavy vehicles.

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

BPH Global has launched a focused R&D collaboration with Temasek Polytechnic to develop seaweed-based bio-stimulants aimed at boosting growth and yields in Southeast Asia's oil palm and rice sectors. Early talks are also underway for a production facility in Indonesia to commercialize these innovations.

Janison Education Group has renewed its $2 million contract with Chartered Accountants Australia and New Zealand, while debuting its AI-powered platform Jai in a landmark commercial deployment.

Codeifai Limited (ASX – CDE) has agreed to acquire Antenna Transfer, an AI-driven quantum-secure platform, marking a strategic expansion into next-generation digital security. The deal positions Codeifai at the forefront of quantum-resilient infrastructure for high-security industries.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.